Indeed, besides interfering with EPC differentiation, the tumor-induced increase in erythropoietin production is also involved in the dynamics triggered by the vascular endothelial growth factor (VEGF), which is produced by cancer cells to enhance tumoral angiogenesis [59] and modulate the antitumoral immune response [60]. The gene discussed is VEGFA; the disease is cancer.